43 patents
Page 2 of 3
Utility
INTERLEUKIN-10 Polypeptide Conjugates, Dimers Thereof, and Their Uses
13 Jan 22
The present invention provides methods for targeting interleukin-10 receptor-expressing cells, and, in particular, inhibiting the growth of such cells by using an interleukin-10 (IL-10) variant conjugated to a biologically active molecule that will affect cells expressing the interleukin-10 receptor.
Mingchao Kang, Yingchun Lu, Nickolas Knudsen, MD Harunur Rashid, Feng Tian
Filed: 19 Oct 19
Utility
Anti-CD3 Antibody Folate Bioconjugates and Their Uses
14 Oct 21
Described herein are novel anti-CD3 Folate antibodies and uses thereof in the treatment of diseases or conditions that would benefit from such.
Md Harunur Rashid, Ying Sun, Feng Tian, Sung Ju Moon
Filed: 28 Aug 19
Utility
Compositions Containing, Methods Involving, and Uses of Non-natural Amino Acid Linked Dolastatin Derivatives
9 Sep 21
Disclosed herein are non-natural amino acids and dolastatin analogs that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides.
Zhenwei MIAO, Kyle ATKINSON, Sandra BIROC, Timothy BUSS, Melissa NEAL, Vadim KRAYNOV, Robin MARSDEN, Jason PINKSTAFF, Lillian SKIDMORE, Ying SUN, Agnieszka SZYDLIK, Delia Ianina LOPEZ DE VALENTA
Filed: 5 Jan 21
Utility
Modified FGF-21 Polypeptides and Their Uses
26 Aug 21
Modified FGF-21 polypeptides and uses thereof are provided.
Thomas P. CUJEC, Roberto MARIANI, Anna-Maria A. HAYS PUTNAM, William M. KEEFE, Nick KNUDSEN, Lillian SKIDMORE, Jason PINKSTAFF, Vadim KRAYNOV
Filed: 2 Feb 21
Utility
Pegylated Porcine Interferon and Methods of Use Thereof
17 Jun 21
Disclosed herein are porcine interferon alpha variants (pINF-α) comprising a synthetic amino acid at select locations in pINF-α and a one or two amino acid insertion in the N-terminus after removal of the signal peptide.
Peter Connor CANNING, Nickolas KNUDSEN, Lillian SKIDMORE
Filed: 26 Feb 21
Utility
Pegylated porcine interferon and methods of use thereof
30 Mar 21
Disclosed herein are porcine interferon alpha variants (pIFN-α) comprising a synthetic amino acid at select locations in pIFN-α and a one or two amino acid insertion in the N-terminus after removal of the signal peptide.
Peter Connor Canning, Nickolas Knudsen, Lillian Skidmore
Filed: 16 Jun 17
Utility
Modified FGF-21 polypeptides and their uses
30 Mar 21
Modified FGF-21 polypeptides and uses thereof are provided.
Thomas P. Cujec, Roberto Mariani, Anna-Maria A. Hays Putnam, William M. Keefe, Nick Knudsen, Lillian Skidmore, Jason Pinkstaff, Vadim Kraynov
Filed: 17 Jun 19
Utility
Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives
23 Mar 21
Disclosed herein are non-natural amino acids and dolastatin analogs that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides.
Zhenwei Miao, Kyle Atkinson, Sandra Biroc, Timothy Buss, Melissa Neal, Vadim Kraynov, Robin Marsden, Jason Pinkstaff, Lillian Skidmore, Ying Sun, Agnieszka Szydlik, Delia Ianina Lopez De Valenta
Filed: 12 Sep 17
Utility
Porcine G-CSF Variants and Their Uses
25 Feb 21
The present invention relates to variants of porcine granulocyte colony stimulating factor (pG-CSF).
Peter Connor CANNING, Nickolas KNUDSEN, Md Harunur RASHID
Filed: 10 Oct 18
Utility
Humanized Anti-prostate -Specific Membrane Antigen (Psma) Antibody Drug Conjugates
21 Jan 21
The invention relates to prostate specific membrane antigen humanized antibodies (anti-PSMA) and anti-PSMA antibody drug conjugates.
Shivarupam Bhowmik, Jianing Wang, Jinming Xia, William Brady, Feng Tian
Filed: 29 Mar 19
Utility
Methods and Compositions for Promoting Non-natural Amino Acid-containing Protein Production
21 Jan 21
Disclosed herein are methods and compositions for generation of cell lines to promote unnatural amino acid-containing protein production using genome engineering technology.
Sigeng Chen, Yingchun LU, Feng TIAN
Filed: 2 Jun 18
Utility
Antibody Peptide Conjugates That Have Agonist Activity at Both the Glucagon and Glucagon-like Peptide 1 Receptors
16 Dec 20
Described are antibody peptide conjugates (APCs) comprising an antibody conjugated to a peptide analog of glucagon, which have been modified to be resistant to cleavage and inactivation by dipeptidyl peptidase IV (DPP-IV) and to increase in vivo half-life of the peptide analog while enabling the peptide analog to have agonist activity at the glucagon (GCG) receptor and the glucagon-like peptide 1 (GLP-1) receptor and the use of such APCs for treatment of metabolic disorders such as diabetes, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and obesity.
Paul E. Carrington, Grigori Ermakov, Robert M. Garbaccio, Wolfgang Seghezzi, Elisabetta Bianchi, Federica Orvieto, Dennis Gately, Nick Knudsen, Anthony Manibusan
Filed: 26 Aug 20
Utility
Modified Relaxin Polypeptides and Their Uses
18 Nov 20
Modified relaxin polypeptides and their uses thereof are provided.
Vadim KRAYNOV, Nick KNUDSEN, Amha HEWET, Kristine DE DIOS, Jason PINKSTAFF, Lorraine SULLIVAN
Filed: 26 May 20
Utility
Modified Relaxin Polypeptides and Their Uses
18 Nov 20
Modified relaxin polypeptides and their uses thereof are provided
Vadim KRAYNOV, Nick KNUDSEN, Amha HEWET, Kristine DE DIOS, Jason PINKSTAFF, Lorraine SULLIVAN
Filed: 27 May 20
Utility
Prostate-specific membrane antigen antibody drug conjugates
12 Oct 20
This invention relates to prostate-specific membrane antigen (PSMA) antibodies and antibody drug conjugates comprising at least one non-naturally-encoded amino acid.
Richard S. Barnett, Feng Tian, Anna-Maria A. Hays Putnam, Marco Gymnopoulos, Nick Knudsen, Andrew Beck, Ying Sun
Filed: 6 Jun 13
Utility
Antibody peptide conjugates that have agonist activity at both the glucagon and glucagon-like peptide 1 receptors
12 Oct 20
Described are antibody peptide conjugates (APCs) comprising an antibody conjugated to a peptide analog of glucagon, which have been modified to be resistant to cleavage and inactivation by dipeptidyl peptidase IV (DPP-IV) and to increase in vivo half-life of the peptide analog while enabling the peptide analog to have agonist activity at the glucagon (GCG) receptor and the glucagon-like peptide 1 (GLP-1) receptor and the use of such APCs for treatment of metabolic disorders such as diabetes, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and obesity.
Paul Carrington, Grigori Ermakov, Robert M. Garbaccio, Wolfgang Seghezzi, Elisabetta Bianchi, Federica Orvieto, Dennis Gately, Nick Knudsen, Anthony Manibusan
Filed: 3 Oct 16
Utility
Methods of treatment using modified relaxin polypeptides comprising a non-naturally encoded amino acid
24 Aug 20
Modified relaxin polypeptides and their uses thereof are provided.
Vadim Kraynov, Nick Knudsen, Amha Hewet, Kristine De Dios, Jason Pinkstaff, Lorraine Sullivan
Filed: 25 Feb 19
Utility
Modified relaxin polypeptides comprising a non-naturally encoded amino acid in the A chain
6 Jul 20
Modified relaxin polypeptides and their uses thereof are provided.
Vadim Kraynov, Nick Knudsen, Amha Hewet, Kristine De Dios, Jason Pinkstaff, Lorraine Sullivan
Filed: 29 Mar 18
Utility
Antibody Drug Conjugate for Anti-inflammatory Applications
27 May 20
Antibody drug conjugates (ADCs) comprising an antibody conjugated to an anti-inflammatory therapeutic agent via a phosphate-based linker with tunable extracellular and intracellular stability are described.
Philip E. Brandish, Robert M Garbaccio, Jeffrey Kern, Linda Liang, Sanjiv Shah, Dennis Zaller, Andrew Beck, Dennis Gately, Nick Knudsen, Anthony Manibusan, Jianing Wang, Ying Sun
Filed: 29 Sep 16
Utility
Phosphate based linkers for intracellular delivery of drug conjugates
3 Feb 20
Phosphate-based linkers with tunable stability for intracellular delivery of drug conjugates are described.
Robert M. Garbaccio, Jeffrey Kern, Philip E. Brandish, Sanjiv Shah, Linda Liang, Ying Sun, Jianing Wang, Nick Knudsen, Andrew Beck, Anthony Manibusan, Dennis Gately
Filed: 29 Mar 15